ClinicalTrials.gg
Active, not recruitingNCT06340048HEAL-AHFUpdated Feb 10, 2026

Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure

A Phase 1/2 interventional study of HiCM-188 therapy in Heart Failure, sponsored by HELP Therapeutics Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by HELP Therapeutics Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Sep 2023, registered Jan 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 375 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.

Planned enrollment
213th of 246
36 · median 127
Started
2023
with 41 others
Phase 1/2
14 of 375
7 open now
Primary completion
2026-11
later than 80 of 181 live
Registered
233rd of 375
by date

Among the 375 studies in Heart Failure with a site in China, this one is the 213th largest by planned enrollment of the 246 interventional ones that give a count, is one of 42 that started in 2023, is one of 14 in phase 1/2, reaches primary completion later than 80 of the 181 other live ones, and was the 233rd registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

162 of the 375 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Heart Failure with a site in China, or all of them as a file.
02

Study summary

The purpose of this clinical study is to evaluate the feasibility, safety and efficacy of intramyocardial injection of human induce pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting (CABG) surgery in patients with severe chronic ischemic heart failure.

Read the detailed description

This is a single center, open-label, three-group dose-escalation (phase I) study followed by dose-extension (phase IIa) study in up to 36 severe ischemic heart failure patients. It is estimated that up to 18 phase I patients will be received HiCM-188 intramyocardial injection during CABG surgery. The maximum number of subjects after dose escalation and dose extension studies in each dose group is 12. All the subjects need take immunosuppressant after transplantation.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. Willingness and ability to give written
  3. Nuclide-myocardial metabolic perfusion imaging or Magnetic Resonance Imaging (MRI) revealed infarcted myocardium in the left anterior descending branch (LAD) coronary artery supply area
  4. \<50% as assessed by Echocardiography or LVEF≤40% as assessed by MRI
  5. Patients have indications for Coronary Artery Bypass Grafting

Exclusion criteria

Exclusion Criteria:

  1. Presence of a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy device (CRT)
  2. Diagnosed with within 5 years
  3. disease
  4. Recipients of organ transplant.
  5. Patients undergoing other surgical operations (excluding resection of ventricular aneurysm and left atrial appendage excision/occlusion).
  6. Severe ventricular arrhythmia
  7. to CABG surgery
  8. Contraindication to cardiac MRI or PET/CT scan.
  9. Contraindication to
  10. Participation in another clinical trial within 3 months prior to screening
  11. Pregnancy, lactation, or a positive serum pregnancy test
  12. Any other condition considered by the investigator to be inappropriate for inclusion in this clinical trial
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    HiCM-188 Low dose therapy

    Intramyocardial injection of HiCM-188 (50 million) during CABG surgery.

    Drug: HiCM-188 therapy

  • Experimental
    HiCM-188 Medium dose therapy

    Intramyocardial injection of HiCM-188 (150 million) during CABG surgery.

    Drug: HiCM-188 therapy

  • Experimental
    HiCM-188 High dose therapy

    Intramyocardial injection of HiCM-188 (450 million) during CABG surgery.

    Drug: HiCM-188 therapy

Interventions

  • Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes (HiCM-188) during coronary artery bypass grafting surgery

06

What researchers measure

Primary outcomes

  1. The incidence of major Serious Adverse Events (SAE)

    The incidence of major Serious Adverse Events (SAE) within the first month after surgery, including pericardial tamponade, nonfatal myocardial infarction, stroke, and all-cause death

    Time frame: Within the first month after surgery

Secondary outcomes

  1. Grade 4 or above arrhythmias Related to HiCM-188 Cell Therapy

    Grade 4 or above arrhythmias associated with the HiCM-188 therapy within the first month after surgery

    Time frame: Within the first month after surgery

  2. The incidence of tumor

    assessed by PET whole-body imaging at baseline and 12 months after HiCM-188 therapy

    Time frame: 12 months after surgery

  3. Left ventricular geometry as assessed by cardiac magnetic resonance imaging (MRI)

    Left ventricular wall thickness, interventricular septum thickness

    Time frame: Baseline, 6 and 12 months after surgery

  4. Size of myocardial infarction as assessed by MRI

    Size of myocardial infarction

    Time frame: Baseline, 6 and 12 months after surgery

  5. Ventricular wall motion as assessed by MRI

    Ventricular wall motion

    Time frame: Baseline, 6 and 12 months after surgery

  6. Left ventricular ejection fraction as assessed by MRI

    Left ventricular ejection fraction

    Time frame: Baseline, 6 and 12 months after surgery

  7. Cardiac Volumes as assessed by MRI

    Left ventricular end-diastolic volume (LVEDV), Left ventricular end-systolic volume (LVESV) and Stroke Volume (SV)

    Time frame: Baseline, 6 and 12 months after surgery

  8. Cardiac output (CO) as assessed by MRI

    Cardiac output (CO)

    Time frame: Baseline, 6 and 12 months after surgery

  9. End-diastolic myocardial mass as assessed by MRI

    End-diastolic myocardial mass

    Time frame: Baseline, 6 and 12 months after surgery

  10. Left ventricular ejection fraction (LVEF) as assessed by Echocardiography

    Left ventricular ejection fraction

    Time frame: Baseline, 6 and 12 months after surgery

  11. Fractional shortening (FS) as assessed by Echocardiography

    Fractional shortening

    Time frame: Baseline, 6 and 12 months after surgery

  12. Left ventricular dimensions as assessed by Echocardiography

    Left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter(LVESD)and left atrial diameter

    Time frame: Baseline, 6 and 12 months after surgery

  13. Cardiac Volumes as assessed by Echocardiography

    Left ventricular end- diastolic volume (LVEDV) and Left ventricular end-systolic volume(LVESV)

    Time frame: Baseline, 6 and 12 months after surgery

  14. Mitral valve inflow spectrum(E/A) as assessed by Echocardiography

    Mitral valve inflow spectrum (E/A)

    Time frame: Baseline, 6 and 12 months after surgery

  15. Longitudinal strain as assessed by Echocardiography

    Longitudinal strain

    Time frame: Baseline, 6 and 12 months after surgery

  16. Myocardial viability as assessed by SPECT

    Myocardial viability

    Time frame: Baseline, 6 and 12 months after surgery

  17. Myocardial blood flow as assessed by SPECT

    Myocardial blood flow

    Time frame: Baseline, 6 and 12 months after surgery

  18. NT-proBNP Levels

    The changes of NT-proBNP Levels

    Time frame: Baseline, 6 and 12 months after surgery

  19. 6-minute walking distance

    The changes of 6-minute walking distance at 6M and 12M after HiCM-188 therapy

    Time frame: Baseline, 6 and 12 months after surgery

  20. New York Heart Association (NYHA) functional classification

    The changes of New York Heart Association (NYHA) functional classification at 6M and 12M after HiCM-188 therapy

    Time frame: Baseline, 6 and 12 months after surgery

  21. Changes of Quality of Life (QoL) as assessed by Minnesota Living with Heart Failure Questionnaire (MLHFQ)

    The MLHFQ is a self-administered disease-specific outcome measure instrument for patients with heart failure (HF), comprising 21 items rated on Likert scales, representing different degrees of impact of HF on QoL. The MLHFQ scores are on a range of 0-105, in which higher scores reflect better health status.

    Time frame: Baseline, 6 and 12 months after surgery

  22. Changes of Quality of Life(QOL) as assessed by 36-Item Short Form Survey (SF-36)

    The 36-Item Short Form Survey(SF-36) is a self-administered outcome measure instrument that comprises 36 items grouped into 8 dimensions: limitations in physical activities because of health problems, limitations in social activities because of physical or emotional problems, limitations in usual role activities because of physical health problems, bodily pain, general mental health, limitations in usual role activities because of emotional problems, vitality, general health perceptions. The SF-36 scores are on a range of 0-100, in which higher scores reflect better health status.

    Time frame: Baseline, 6 and 12 months after surgery

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Nov 2026, 38 months after the start.

Of 43 phase 1/2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's planned 38 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2024
First posted
Apr 1, 2024
StartActual
Sep 5, 2023
Primary completionEst.
Nov 10, 2026
CompletionEst.
May 10, 2027
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06340048
Lead sponsor
HELP Therapeutics Co., Ltd.
Collaborators
TEDA International Cardiovascular Hospital
Responsible party
Sponsor
First posted
Apr 1, 2024
Start date
Sep 5, 2023
Primary completion
Nov 10, 2026 (estimated)
Completion
May 10, 2027 (estimated)
Last update
Feb 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HICM-188

Start the discussion